Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.

@article{Theunissen2017StandardizedFC,
  title={Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.},
  author={P. Theunissen and E. Mejstř{\'i}kov{\'a} and L. Sędek and A. van der Sluijs-Gelling and G. Gaipa and M. Bartels and E. Sobral da Costa and M. Kotrov{\'a} and M. Nov{\'a}kov{\'a} and E. Sonneveld and C. Buracchi and P. Bonaccorso and Elen Oliveira and J. T. te Marvelde and T. Szczepański and L. Lhermitte and O. Hrusak and Q. L{\'e}crevisse and G. Grigore and E. Froňkov{\'a} and J. Trka and M. Br{\"u}ggemann and A. Orfao and J. V. van Dongen and V. V. D. van der Velden},
  journal={Blood},
  year={2017},
  volume={129 3},
  pages={
          347-357
        }
}
A fully-standardized EuroFlow 8-color antibody panel and laboratory procedure was stepwise designed to measure minimal residual disease (MRD) in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients with a sensitivity of ≤10-5, comparable to real-time quantitative polymerase chain reaction (RQ-PCR)-based MRD detection via antigen-receptor rearrangements. Leukocyte markers and the corresponding antibodies and fluorochromes were selected based on their contribution in separating BCP… Expand
Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting
Flow Cytometric Minimal Residual Disease Analysis in Acute Leukemia: Current Status
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
...
1
2
3
4
5
...